Efficacy of 2-hydroxypropyl-β-cyclodextrin in Niemann-Pick disease type C model mice and its pharmacokinetic analysis in a patient with the disease

Biological and Pharmaceutical Bulletin

Volumn 38, Issue 6, 2015, Pages 844-851

  Tanaka, Yuta ^a   Yamada, Yusei ^a   Ishitsuka, Yoichi ^a   Matsuo, Muneaki ^b   Shiraishi, Koki ^a   Wada, Koki ^c   Uchio, Yushiro ^a   Kondo, Yuki ^a   Takeo, Toru ^a   Nakagata, Naomi ^a   Higashi, Taishi ^a   Motoyama, Keiichi ^a   Arima, Hidetoshi ^a   Mochinaga, Sakiko ^b   Higaki, Katsumi ^d   Ohno, Kousaku ^e   Irie, Tetsumi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b SAGA UNIVERSITY   (Japan)

^c Fuji   (Japan)

^d TOTTORI UNIVERSITY   (Japan)

^e SAN IN ROSAI HOSPITAL   (Japan)

Author keywords

2 hydroxypropyl cyclodextrin; Niemann Pick type C; Npc1 deficient mouse

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ALANINE AMINOTRANSFERASE; CHOLESTEROL; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE; NPC1 PROTEIN, MOUSE; PROTEIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASE REPORT; CHILD; CHOLESTEROL LIVER LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; EXTRACELLULAR SPACE; FEMALE; GLOMERULUS FILTRATION RATE; HEPATOSPLENOMEGALY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER INJURY; MALE; MOUSE; NIEMANN PICK DISEASE; NONHUMAN; PRESCHOOL CHILD; SURVIVAL TIME; VOLUME OF DISTRIBUTION; WEIGHT CHANGE; ANIMAL; BLOOD; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; LIVER; LIVER DISEASES; METABOLISM; NIEMANN-PICK DISEASE, TYPE C; SOLUBILITY;

ANIMALS; BETA-CYCLODEXTRINS; CHOLESTEROL; DISEASE MODELS, ANIMAL; HUMANS; LIVER; LIVER DISEASES; MALE; MICE; MICE, KNOCKOUT; NIEMANN-PICK DISEASE, TYPE C; PROTEINS; SOLUBILITY;

EID: 84936762192     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b14-00726     Document Type: Article

References (25)

1. Carstea ED, Morris JA, Coleman KG, Loftus SK, Zhang D, Cummings C, Gu J, Rosenfeld MA, Pavan WJ, Krizman DB, Nagle J, Polymeropoulos MH, Sturley SL, Ioannou YA, Higgins ME, Comly M, Cooney A, Brown A, Kaneski CR, Blanchette-Mackie EJ, Dwyer NK, Neufeld EB, Chang TY, Liscum L, Strauss JF 3rd, Ohno K, Zeigler M, Carmi R, Sokol J, Markie D, O'Neill RR, van Diggelen OP, Elleder M, Patterson MC, Brady RO, Vanier MT, Pentchev PG, Tagle DA. Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science, 277, 228-231 (1997).
2. Naureckiene S, Sleat DE, Lackland H, Fensom A, Vanier MT, Wattiaux R, Jadot M, Lobel P. Identification of HE1 as the second gene of Niemann-Pick C disease. Science, 290, 2298-2301 (2000).
3. Vanier MT. Niemann-Pick disease type C. Orphanet J. Rare Dis., 5, 16 (2010).
4. Matsuo M, Togawa M, Hirabaru K, Mochinaga S, Narita A, Adachi M, Egashira M, Irie T, Ohno K. Effects of cyclodextrin in two patients with Niemann-Pick type C disease. Mol. Genet. Metab., 108, 76-81 (2013).
5. Wojtanik KM, Liscum L. The transport of low density lipoprotein-derived cholesterol to the plasma membrane is defective in NPC1 cells. J. Biol. Chem., 278, 14850-14856 (2003).
6. Peake KB, Vance JE. Normalization of cholesterol homeostasis by 2-hydroxypropyl-beta-cyclodextrin in neurons and glia from Niemann-Pick C1 (NPC1)-deficient mice. J. Biol. Chem., 287, 9290-9298 (2012).
7. -/- mouse. Proc. Natl. Acad. Sci. U.S.A., 106, 2377-2382 (2009).
8. Davidson CD, Ali NF, Micsenyi MC, Stephney G, Renault S, Dobrenis K, Ory DS, Vanier MT, Walkley SU. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS ONE, 4, e6951 (2009).
9. Ramirez CM, Liu B, Taylor AM, Repa JJ, Burns DK, Weinberg AG, Turley SD, Dietschy JM. Weekly cyclodextrin administration normalizes cholesterol metabolism in nearly every organ of the Niemann-Pick type C1 mouse and markedly prolongs life. Pediatr. Res., 68, 309-315 (2010).
10. Yu D, Swaroop M, Wang M, Baxa U, Yang R, Yan Y, Coksaygan T, DeTolla L, Marugan JJ, Austin CP, McKew JC, Gong DW, Zheng W. Niemann-Pick disease type c: induced pluripotent stem cell-derived neuronal cells for modeling neural disease and evaluating drug efficacy. J. Biomol. Screen., 19, 1164-1173 (2014).
11. Loftus SK, Morris JA, Carstea ED, Gu JZ, Cummings C, Brown A, Ellison J, Ohno K, Rosenfeld MA, Tagle DA, Pentchev PG, Pavan WJ. Murine model of Niemann-Pick C disease: mutation in a cholesterol homeostasis gene. Science, 277, 232-235 (1997).
12. Tanaka Y, Ishitsuka Y, Yamada Y, Kondo Y, Takeo T, Nakagata N, Higashi T, Motoyama K, Arima H, Matsuo M, Higaki K, Ohno K, Irie T. Influence of Npc1 genotype on the toxicity of hydroxypropyl-β-cyclodextrin, a potentially therapeutic agent, in Niemann-Pick type C disease models. Mol. Genet. Metab. Rep., 1, 19-30 (2014).
13. Frijlink HW, Visser J, Drenth BF. Determination of cyclodextrins in biological fluids by high-performance liquid chromatography with negative colorimetric detection using post-column complexation with phenolphthalein. J. Chromatogr., 415, 325-333 (1987).
14. Szathmary SC. Determination of hydroxypropyl-beta-cyclodextrin in plasma and urine by size-exclusion chromatography with post-column complexation. J. Chromatogr., 487, 99-105 (1989).
15. Aqul A, Liu B, Ramirez CM, Pieper AA, Estill SJ, Burns DK, Liu B, Repa JJ, Turley SD, Dietschy JM. Unesterified cholesterol accumulation in late endosomes/lysosomes causes neurodegeneration and is prevented by driving cholesterol export from this compartment. J. Neurosci., 31, 9404-9413 (2011).
16. Tamura A, Yui N. Lysosomal-specific cholesterol reduction by biocleavable polyrotaxanes for ameliorating Niemann-Pick type C disease. Sci. Rep., 4, 4356 (2014).
17. Lopez AM, Terpack SJ, Posey KS, Liu B, Ramirez CM, Turley SD. Systemic administration of 2-hydroxypropyl-β-cyclodextrin to symptomatic Npc1-deficient mice slows cholesterol sequestration in the major organs and improves liver function. Clin. Exp. Pharmacol. Physiol., 41, 780-787 (2014).
18. Frijlink HW, Visser J, Hefting NR, Oosting R, Meijer DK, Lerk CF. The pharmacokinetics of beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin in the rat. Pharm. Res., 7, 1248-1252 (1990).
19. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci., 86, 147-162 (1997).
20. Rosenbaum AI, Zhang G, Warren JD, Maxfield FR. Endocytosis of beta-cyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cells. Proc. Natl. Acad. Sci. U.S.A., 107, 5477-5482 (2010).
21. Camargo F, Erickson RP, Garver WS, Hossain GS, Carbone PN, Heidenreich RA, Blanchard J. Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease. Life Sci., 70, 131-142 (2001).
22. Liu B, Ramirez CM, Miller AM, Repa JJ, Turley SD, Dietschy JM. Cyclodextrin overcomes the transport defect in nearly every organ of NPC1 mice leading to excretion of sequestered cholesterol as bile acid. J. Lipid Res., 51, 933-944 (2010).
23. Rosenbaum AI, Maxfield FR. Niemann-Pick type C disease: molecular mechanisms and potential therapeutic approaches. J. Neurochem., 116, 789-795 (2011).
24. Vance JE, Peake KB. Function of the Niemann-Pick type C proteins and their bypass by cyclodextrin. Curr. Opin. Lipidol., 22, 204-209 (2011).
25. -/- mice without carrying cholesterol through the bloodstream. J. Lipid Res., 53, 2331-2342 (2012).